Leonardo DRS, Inc. DRS 深 滬
等待開盤 09-25 09:30:00 美东时间
42.55
-0.550
-1.28%
華盛通- 最 高43.73
- 今 開43.17
- 成交量 65.20万股
- 最 低 42.53
- 昨 收 43.10
- 總市值 113.18亿
- 52周最高 49.22
- 市盈率 靜 53.47
- 換手率 0.25%
- 52周最低 27.50
- 委 比 94.04%
- 總股本 2.66亿
- 歷史最高 49.22
- 量 比 0.49
- 振 幅 2.78%
- 歷史最低 8.84
- 每 手 1
- 風險率 5.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Gain Therapeutics Begins GT-02287 Phase 1b Extension Study Allowing Participants To Continue Treatment For Additional Nine Months
Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing scheduleThe Phase 1b study enrolled 21 subjects and the last
09-18 19:45
The Brink's declares $0.255 dividend
The Brink's (NYSE:BCO) declares $0.255/share quarterly dividend, in line with previous. Forward yield 0.89% Payable Dec. 1; to shareholders of record Nov. 3; ex-div Nov. 3. The company has now announc...
09-18 13:05
Johnson & Johnson Kicks Off 'Powerful New Product Cycle': Analyst
Johnson & Johnson analyst Asad Haider says Inlexzo is currently the only intravesical iDRS to deliver cancer meds directly into the bladder.
09-10 22:41
强生(JNJ.US)获FDA批准突破性疗法 超80%患者肿瘤完全消失
结果显示，使用Inlexzo治疗的BCG无应答NMIBC患者中有82%达到完全缓解(CR)，即治疗后未观察到癌症迹象(95% CI：72-90)。
09-10 08:52
What's Next: AeroVironment's Earnings Preview
AeroVironment (NASDAQ:AVAV) is set to give its latest quarterly earnings report...
09-08 22:01
Opus Genetics Announces First Patient Has Been Dosed In Its Phase 3 Lynx-3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% For Treating Chronic Night Driving Impairment In Keratorefractive Patients With Reduced Mesopic Vision
Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small-molecule therapies for other ophthalmic disorders, today announced
09-04 20:14
艾伯维下注迷幻药
大厂开始下场布局迷幻药了。 近日，艾伯维以12亿美元收购了Gilgamesh Pharmaceuticals公司的迷幻药GM-2505（Bretisiloci...
08-27 12:02
AbbVie To Acquire Gilgamesh's Bretisilocin, A Phase 2 Psychedelic Therapy For Major Depressive Disorder; Terms Not Disclosed
Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD).Bretisilocin is a novel,
08-25 21:00
美股盘后 | Caris Life Sciences, Inc.涨4.02%，AST SPACEMOBILE涨2.19%
Caris Life Sciences, Inc.涨4.02%；AST SPACEMOBILE涨2.19%；CGI集团涨1.99%
08-23 06:11
